Sachpekidis C - Search Results

1

¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C. Smailagic N, et al. Among authors: sachpekidis c. Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2. Cochrane Database Syst Rev. 2015. PMID: 25629415 Free PMC article. Review.

2

Longitudinal studies of the ¹⁸F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT.

Sachpekidis C, Anwar H, Winkler JK, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Cancer Immunol Immunother. 2018 Aug;67(8):1261-1270. doi: 10.1007/s00262-018-2183-3. Epub 2018 Jun 5. Cancer Immunol Immunother. 2018. PMID: 29872898 Free PMC article.

3

Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.

Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):386-96. doi: 10.1007/s00259-014-2944-y. Epub 2014 Oct 31. Eur J Nucl Med Mol Imaging. 2015. PMID: 25359635

4

(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.

Sachpekidis C, Mai EK, Goldschmidt H, Hillengass J, Hose D, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Clin Nucl Med. 2015 Jun;40(6):e300-7. doi: 10.1097/RLU.0000000000000773. Clin Nucl Med. 2015. PMID: 25783508

5

Treatment response evaluation with ¹⁸F-FDG PET/CT and ¹⁸F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Sachpekidis C, Hillengass J, Goldschmidt H, Wagner B, Haberkorn U, Kopka K, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):50-62. doi: 10.1007/s00259-016-3502-6. Epub 2016 Aug 29. Eur J Nucl Med Mol Imaging. 2017. PMID: 27573638 Free article. Clinical Trial.

6

The role of interim ¹⁸F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma.

Sachpekidis C, Anwar H, Winkler J, Kopp-Schneider A, Larribere L, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1289-1296. doi: 10.1007/s00259-018-3972-9. Epub 2018 Feb 24. Eur J Nucl Med Mol Imaging. 2018. PMID: 29478079 Clinical Trial.

7

Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD.

Flechsig P, Hural O, Kreuter M, Eichhorn M, HEUßEL G, Sachpekidis C, Kauczor HU, Haberkorn U, Heussel CP, Eichinger M. Flechsig P, et al. Among authors: sachpekidis c. In Vivo. 2018 Nov-Dec;32(6):1457-1462. doi: 10.21873/invivo.11399. In Vivo. 2018. PMID: 30348701 Free PMC article.

8

Detection of a primary tumor in the area of the renal artery with 18F-FDG PET/CT in a patient with metastatic undifferentiated sarcoma and a history of mid-aortic syndrome: A case report.

Sachpekidis C, Langer R, Kollàr A, Wartenberg J. Sachpekidis C, et al. Medicine (Baltimore). 2016 Aug;95(34):e4622. doi: 10.1097/MD.0000000000004622. Medicine (Baltimore). 2016. PMID: 27559958 Free PMC article.

9

Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1932-1943. doi: 10.1007/s00259-020-05137-7. Epub 2020 Dec 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33336264 Free PMC article.

10

Absolute number of new lesions on ¹⁸F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab.

Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Anwar H, et al. Among authors: sachpekidis c. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):376-383. doi: 10.1007/s00259-017-3870-6. Epub 2017 Nov 10. Eur J Nucl Med Mol Imaging. 2018. PMID: 29124281 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

107 results

Search Page